Signaling pathways in breast cancer: therapeutic targeting of the microenvironment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is a leading global cancer in women, necessitating a deep understanding of its biology for effective treatment.
• Cell cycle dysregulation is a hallmark of many cancers, including breast cancer.
• Targeted therapies, such as cyclin-dependent kinase inhibitors (CDKIs) and agents inhibiting signaling pathways (Notch, Wnt, SHH), are emerging as crucial in breast cancer treatment.

Purpose of the Study:

• To summarize recent findings on signaling pathways in breast cancer.
• To discuss the therapeutic potential of targeting these pathways and the tumor microenvironment.
• To highlight the role of CDKIs, specifically Palbocyclib, in breast cancer therapy.

Main Methods:

• Review of current literature on breast cancer signaling pathways.
• Analysis of targeted agents, including selective and non-selective CDKIs.
• Consideration of tumor microenvironment as a therapeutic target.

Main Results:

• Cyclin-dependent kinase inhibitors (CDKIs) are effective in monotherapy and combination treatments.
• Palbocyclib, a CDKI, demonstrates significant progression-free survival in estrogen receptor-positive breast cancer.
• The tumor microenvironment is a critical factor influencing treatment response and a potential target for combination therapies.

Conclusions:

• Targeting cell cycle regulation and specific signaling pathways offers promising therapeutic avenues for breast cancer.
• Palbocyclib represents a significant advancement in targeted therapy for ER-positive breast cancer.
• Combination therapies involving targeting the tumor microenvironment may improve treatment outcomes.